Back to Search
Start Over
Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations
- Source :
- Blood, Blood, American Society of Hematology, 2015, 125 (5), pp.856-859. ⟨10.1182/blood-2014-09-600874⟩, Blood, 125(5), 856-859. American Society of Hematology
- Publication Year :
- 2015
- Publisher :
- American Society of Hematology, 2015.
-
Abstract
- An unresolved issue in chronic lymphocytic leukemia (CLL) is whether IGHV3-21 gene usage, in general, or the expression of stereotyped B-cell receptor immunoglobulin defining subset # 2 (IGHV3-21/IGLV3-21), in particular, determines outcome for IGHV3-21-utilizing cases. We reappraised this issue in 8593 CLL patients of whom 437 (5%) used the IGHV3-21 gene with 254/437 (58%) classified as subset # 2. Within subset # 2, immunoglobulin heavy variable (IGHV)-mutated cases predominated, whereas non-subset # 2/IGHV3-21 was enriched for IGHV-unmutated cases (P =.002). Subset # 2 exhibited significantly shorter time-to-first-treatment (TTFT) compared with non-subset # 2/IGHV3-21 (22 vs 60 months, P =.001). No such difference was observed between non-subset # 2/IGHV3-21 vs the remaining CLL with similar IGHV mutational status. In conclusion, IGHV3-21 CLL should not be axiomatically considered a homogeneous entity with adverse prognosis, given that only subset # 2 emerges as uniformly aggressive, contrasting non-subset # 2/IGVH3-21 patients whose prognosis depends on IGHV mutational status as the remaining CLL.
- Subjects :
- Male
Oncology
medicine.medical_specialty
Chronic lymphocytic leukemia
Immunology
B-cell receptor
Gene Rearrangement, B-Lymphocyte, Heavy Chain
Antineoplastic Agents
Biology
Biochemistry
Time-to-Treatment
Genetic Heterogeneity
03 medical and health sciences
0302 clinical medicine
Internal medicine
medicine
Humans
10. No inequality
ComputingMilieux_MISCELLANEOUS
Survival analysis
Aged
030304 developmental biology
[SDV.GEN]Life Sciences [q-bio]/Genetics
B-Lymphocytes
0303 health sciences
Lymphoid Neoplasia
Hematology
Gene Expression Regulation, Leukemic
Genetic heterogeneity
Cell Biology
Middle Aged
Prognosis
medicine.disease
Leukemia, Lymphocytic, Chronic, B-Cell
Survival Analysis
Treatment Outcome
030220 oncology & carcinogenesis
biology.protein
Immunoglobulin heavy chain
Female
Somatic Hypermutation, Immunoglobulin
Antibody
Immunoglobulin Heavy Chains
IGHV@
Subjects
Details
- ISSN :
- 15280020 and 00064971
- Volume :
- 125
- Database :
- OpenAIRE
- Journal :
- Blood
- Accession number :
- edsair.doi.dedup.....3af82c0b22edf5f8a9a1063132ac6a41